Shelter Pharma (543963) Q4 20/21 earnings summary

Executive summary

• FY ended Mar. 31, 2021 revenue was ₹22.48 crore and net profit was ₹5.10 lakh; COVID-related travel and transport disruption reduced sales.

• Auditors gave an unqualified opinion, concluding the statements presented a true and fair view under Indian accounting principles.

Financial highlights

• Revenue from operations fell to ₹22.48 crore from ₹30.07 crore in FY20; other income was ₹44,641 vs ₹47,023.

• Profit before tax was ₹6.85 lakh vs ₹9.39 lakh; profit after tax was ₹5.10 lakh vs ₹7.08 lakh.

• Total expenses declined to ₹22.42 crore from ₹29.98 crore; raw material costs were ₹21.02 crore vs ₹27.11 crore.

• Cash and cash equivalents increased to ₹31.76 lakh from ₹13.39 lakh; inventories were ₹4.02 crore vs ₹4.31 crore.

Outlook and guidance

• Sales affected by COVID-related travel and transportation disruption were expected to recover in the near future.

• No dividend was recommended for FY21 after considering relevant circumstances.